Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.2821 | 0.5 | 0.5 |
Echinococcus multilocularis | glycogen phosphorylase | 0.2821 | 0.5 | 0.5 |
Onchocerca volvulus | Glycogen phosphorylase homolog | 0.2821 | 0.5 | 0.5 |
Echinococcus granulosus | Glycosyl transferase family 35 | 0.2821 | 0.5 | 0.5 |
Schistosoma mansoni | glycogen phosphorylase | 0.2821 | 0.5 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.2821 | 0.5 | 0.5 |
Schistosoma mansoni | glycogen phosphorylase | 0.2821 | 0.5 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.2821 | 0.5 | 0.5 |
Chlamydia trachomatis | glycogen phosphorylase | 0.2821 | 0.5 | 0.5 |
Echinococcus granulosus | glycogen phosphorylase | 0.2821 | 0.5 | 0.5 |
Giardia lamblia | Glycogen phosphorylase | 0.2821 | 0.5 | 0.5 |
Loa Loa (eye worm) | glycogen phosphorylase | 0.2821 | 0.5 | 0.5 |
Echinococcus multilocularis | glycogen phosphorylase | 0.2821 | 0.5 | 0.5 |
Echinococcus multilocularis | Glycosyl transferase, family 35 | 0.2821 | 0.5 | 0.5 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.2821 | 0.5 | 0.5 |
Echinococcus granulosus | glycogen phosphorylase | 0.2821 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | > 100 mg kg-1 | Protection of mice infected with MRSA-32 cell suspension after oral administration of compound | ChEMBL. | 16078842 |
ED50 (functional) | > 100 mg kg-1 | Protection of mice infected with MRSA-32 cell suspension after oral administration of compound | ChEMBL. | 16078842 |
MIC (functional) | = 0.03 ug ml-1 | Minimum inhibitory concentration against methicillin susceptible Staphylococcus aureus | ChEMBL. | 16078842 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.